Login to Your Account



Gilead Sets the Bar at 100% for Interferon-Free HCV Regimen

By Catherine Shaffer
Staff Writer

Monday, November 12, 2012
in_the_clinic.jpg

Gilead Sciences Inc. reported stunning interim results from its Phase II ELECTRON study of 12 weeks of therapy with investigational hepatitis C (HCV) combo sofosbuvir (GS-7977) and GS-5885 with ribavirin showing the best-possible results at four weeks after treatment, a 100 percent sustained virologic response (SVR4).

The trial enrolled 25 patients with genotype 1 chronic HCV, as is considered predictive of cure rates at 12 weeks after treatment (SVR12).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription